Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis

Stopped early · Phase 3

Conditions studied: Osteoarthritis

In brief

An evaluation of the long term safety of tanezumab when administered by subcutaneous injection every 8 weeks for up to 64 weeks

Key facts

Study ID

NCT01127893

Run by

Pfizer

People needed

1

Starts

2010-06-15

Expected to finish

2010-09-29

Last updated by the study team

2021-03-10

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must have participated in specific Phase 3 parent study

You may not qualify if…

• Failed screening for parent study, pregnant women, lactating mothers

Where it is running

• Triwest Research Associates — La Mesa, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.